Myeloma experts weigh in below. Watch the HealthTree University Video to find out more.
Bispecific antibody therapies are currently being tested with many other anti-myeloma therapies. A combination of drugs could provide an even more effective therapy with a longer duration. There are trials for active myeloma patients and a few for those with high-risk smoldering myeloma.
These trials will test for effective combinations, best dosing amounts, side effect profiles, and more. You can look at what active clinical trials are occurring here: HealthTree Myeloma Clinical Trials
Some examples (as of July 2024) include: